Voya Investment Management LLC Sells 4,292 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Voya Investment Management LLC lessened its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 6.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,688 shares of the biotechnology company’s stock after selling 4,292 shares during the period. Voya Investment Management LLC’s holdings in Aurinia Pharmaceuticals were worth $545,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Aurinia Pharmaceuticals by 19.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 8,350 shares during the period. Dark Forest Capital Management LP acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $92,000. Hsbc Holdings PLC boosted its holdings in shares of Aurinia Pharmaceuticals by 48.2% during the 4th quarter. Hsbc Holdings PLC now owns 15,616 shares of the biotechnology company’s stock worth $141,000 after buying an additional 5,080 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after buying an additional 2,635 shares during the period. Finally, MetLife Investment Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 3.5% in the 4th quarter. MetLife Investment Management LLC now owns 85,680 shares of the biotechnology company’s stock valued at $769,000 after acquiring an additional 2,918 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This trade represents a 8.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. The trade was a 9.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock worth $2,753,094 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ:AUPH opened at $8.00 on Friday. The firm has a market cap of $1.09 billion, a P/E ratio of -53.33 and a beta of 1.16. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.99 and a 52-week high of $10.67. The business’s 50 day simple moving average is $8.04 and its two-hundred day simple moving average is $8.21. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.